In 2026, the Inflation Reduction Act (IRA) will allow the Centers for Medicare and Medicaid Services (CMS) to negotiate the maximum price of certain prescription drugs on behalf of Medicare ...
The renewed debate over Most Favored Nation (MFN) drug pricing in the United States reflects a legitimate frustration: ...
In a world where pricing decisions are increasingly interconnected, a risk for healthcare leaders to consider is lagging evidence. ...
While the 15 medications selected for the latest round of the federal government’s drug price negotiation program will face steep cuts in what Medicare will pay, the financial impact to pharmaceutical ...
The Biden administration announced the first 10 drugs selected for Medicare's drug price negotiations, which the White House says will result in lower out-of-pocket costs for seniors. The White House ...
President Donald Trump’s work to lower prescription drug costs for patients will undoubtedly be one of his most significant ...
PhRMA CEO Stephen Ubl applauded the Trump administration for pressuring other nations to pay more, but says he is against efforts to make White House “most-favored-nation” agreements permanent ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. WASHINGTON — Reining in drug ...
The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers ...
Ratain is the Leon O. Jacobson professor of medicine and director of the Center of Personalized Therapeutics at the University of Chicago and chairman of the Board of the Optimal Cancer Care Alliance.
NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle ...
7don MSNOpinion
Drug companies profited from the Big Beautiful Bill. So did Michael Whatley | Opinion
More questions surface about Michael Whatley's stocks in North Carolina's U.S. Senate race.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results